Xenon Pharmaceuticals (XENE) Competitors $39.73 +0.35 (+0.89%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$39.73 0.00 (0.00%) As of 02/21/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends XENE vs. RDY, PCVX, SRPT, QGEN, ASND, ROIV, RVMD, LEGN, BBIO, and AXSMShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Dr. Reddy's Laboratories (NYSE:RDY) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Does the MarketBeat Community prefer RDY or XENE? Xenon Pharmaceuticals received 99 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 70.00% of users gave Xenon Pharmaceuticals an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Xenon PharmaceuticalsOutperform Votes42070.00% Underperform Votes18030.00% Which has more risk & volatility, RDY or XENE? Dr. Reddy's Laboratories has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Is RDY or XENE more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Xenon Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Xenon Pharmaceuticals N/A -24.69%-23.68% Which has preferable earnings and valuation, RDY or XENE? Dr. Reddy's Laboratories has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.35B3.32$668M$0.6321.23Xenon Pharmaceuticals$9.43M321.21-$182.39M-$2.82-14.09 Do analysts rate RDY or XENE? Dr. Reddy's Laboratories currently has a consensus target price of $17.00, indicating a potential upside of 27.48%. Xenon Pharmaceuticals has a consensus target price of $57.38, indicating a potential upside of 44.41%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do institutionals & insiders believe in RDY or XENE? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor RDY or XENE? In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 6 mentions for Dr. Reddy's Laboratories. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Dr. Reddy's Laboratories' score of -0.04 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryXenon Pharmaceuticals beats Dr. Reddy's Laboratories on 12 of the 19 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.03B$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-14.096.1326.4618.82Price / Sales321.21313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book2.806.747.634.64Net Income-$182.39M$138.11M$3.18B$245.69M7 Day Performance2.11%-2.43%-1.91%-2.66%1 Month Performance1.38%-1.91%-0.19%-2.15%1 Year Performance-19.33%-5.03%16.70%12.90% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals2.7111 of 5 stars$39.73+0.9%$57.38+44.4%-18.6%$3.03B$9.43M-14.09210Options VolumeNews CoverageRDYDr. Reddy's Laboratories2.8657 of 5 stars$13.60-2.8%$17.00+25.0%-11.9%$11.35B$311.31B21.6527,048PCVXVaxcyte2.5871 of 5 stars$84.00+0.2%$127.71+52.0%+10.4%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.4948 of 5 stars$107.95-1.4%$176.77+63.8%-19.7%$10.31B$1.24B86.361,314Upcoming EarningsQGENQiagen4.4259 of 5 stars$39.85-0.5%$48.78+22.4%-5.2%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1724 of 5 stars$144.08+1.1%$193.43+34.3%-3.0%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.5635 of 5 stars$10.56+1.1%$18.08+71.2%-7.5%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250LEGNLegend Biotech2.594 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsBBIOBridgeBio Pharma4.7169 of 5 stars$34.90+10.6%$49.08+40.6%+7.9%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5246 of 5 stars$131.15-0.4%$147.13+12.2%+67.8%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Sarepta Therapeutics Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XENE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
